{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mosquito-Borne+Infectious+Diseases&page=2",
    "query": {
      "condition": "Mosquito-Borne Infectious Diseases",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mosquito-Borne+Infectious+Diseases&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T02:11:58.430Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03867331",
      "title": "To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria,Falciparum"
      ],
      "interventions": [
        {
          "name": "5 microgram VLPM01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 microgram VLPM01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 microgram VLPM01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plasmodium falciparum challenge",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "VLP Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 36,
      "start_date": "2019-03-13",
      "completion_date": "2020-05-21",
      "has_results": false,
      "last_update_posted_date": "2021-04-08",
      "last_synced_at": "2026-07-24T02:11:58.430Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03867331"
    },
    {
      "nct_id": "NCT00761020",
      "title": "Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "Mefloquine",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 31,
      "start_date": "2008-09",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2021-04-19",
      "last_synced_at": "2026-07-24T02:11:58.430Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00761020"
    },
    {
      "nct_id": "NCT00537147",
      "title": "Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "West Nile Fever"
      ],
      "interventions": [
        {
          "name": "WN/DEN4delta30 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 26,
      "start_date": "2008-03",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2013-01-03",
      "last_synced_at": "2026-07-24T02:11:58.430Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00537147"
    },
    {
      "nct_id": "NCT03168854",
      "title": "Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasmodium Falciparum Infection"
      ],
      "interventions": [
        {
          "name": "Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Malaria challenge",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-07-26",
      "completion_date": "2019-08-16",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-07-24T02:11:58.430Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03168854"
    },
    {
      "nct_id": "NCT04009824",
      "title": "Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mosquito-Borne Infectious Diseases"
      ],
      "interventions": [
        {
          "name": "AGS-v PLUS Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide ISA-51 Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alhydrogel® Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 51,
      "start_date": "2019-07-08",
      "completion_date": "2021-02-23",
      "has_results": true,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-07-24T02:11:58.430Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04009824"
    },
    {
      "nct_id": "NCT00582504",
      "title": "Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Venezuelan Equine Encephalomyelitis"
      ],
      "interventions": [
        {
          "name": "VEE TC-83",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 500,
      "start_date": "2007-09",
      "completion_date": "2022-06",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-07-24T02:11:58.430Z",
      "location_count": 1,
      "location_summary": "Fort Deterick, Maryland",
      "locations": [
        {
          "city": "Fort Deterick",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00582504"
    },
    {
      "nct_id": "NCT03996967",
      "title": "Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pneumonia, Bacterial",
        "Viral Infection",
        "Clinical Pneumonia",
        "Plasmodium Falciparum Malaria",
        "Malaria",
        "Infections, Respiratory"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Boston University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "2 Months to 5 Years"
      },
      "enrollment_count": 837,
      "start_date": "2019-02-11",
      "completion_date": "2021-04-10",
      "has_results": false,
      "last_update_posted_date": "2022-05-31",
      "last_synced_at": "2026-07-24T02:11:58.430Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03996967"
    },
    {
      "nct_id": "NCT03611946",
      "title": "Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Zika Virus"
      ],
      "interventions": [
        {
          "name": "Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single dose of placebo via subcutaneous injection (0.5ml).",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2018-07-06",
      "completion_date": "2022-03-18",
      "has_results": true,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-07-24T02:11:58.430Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03611946"
    },
    {
      "nct_id": "NCT02433652",
      "title": "Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "Recombinant live attenuated trivalent dengue vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rDEN2Δ30-7169 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2015-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-02-28",
      "last_synced_at": "2026-07-24T02:11:58.430Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02433652"
    },
    {
      "nct_id": "NCT02466750",
      "title": "Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Western Equine Encephalitis"
      ],
      "interventions": [
        {
          "name": "Western Equine Encephalitis (WEE) Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 500,
      "start_date": "2015-12-15",
      "completion_date": "2021-12",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-07-24T02:11:58.430Z",
      "location_count": 1,
      "location_summary": "Fort Deterick, Maryland",
      "locations": [
        {
          "city": "Fort Deterick",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02466750"
    }
  ]
}